publication date: Apr. 4, 2016
20160408 - Apr. 4, 2016
ISSUE 14 – April 8, 2016PDF



Jacks, Jaffee, Singer Named Co-Chairs of NCI’s Moonshot Blue Ribbon Panel

NCI announced a panel of advisors to inform the scientific direction and goals of Vice President Joe Biden’s National Cancer Moonshot Initiative.

The 28-member Blue Ribbon Panel, a committee of scientific experts, cancer leaders, and patient advocates, will serve as the working group of the National Cancer Advisory Board and provide scientific guidance from opinion leaders in the cancer community.

 

FDA Allows Containment Bags for Power Morcellators; Paper Reports Leakage

FDA granted permission to an Irish company to market the “PneumoLiner,” a first-of-its-kind containment system indicated for isolating and containing uterine tissue during a minimally invasive hysterectomy or myomectomy. The agency announced its action April 7.

Gynecologists will soon be able to use the containment system—designed to prevent dissemination of potentially cancerous tissue—with specific models of power morcellators to conduct laparoscopic surgery in a limited population of women.

ORIEN Partners with Pharma Companies to Develop Precision Medicines with Big Data

The Oncology Research Information Exchange Network and M2Gen formed a bioinformatics collaboration with Celgene Corp.

The partnership, announced April 7, is called the ORIEN Avatar Research Program. The initiative is managed by M2Gen and is designed to generate large amounts of genetic and clinical information on patients consenting to the Total Cancer Care Protocol, a standard operating protocol used by ORIEN member institutions.

Caligiuri Named President-Elect of AACR

Michael Caligiuri was named president-elect by the members of the American Association for Cancer Research. He will officially become president-elect at the AACR’s annual meeting in New Orleans, April 16-20, and will assume the presidency at the 2017 annual meeting.

Caligiuri is director of The Ohio State University Comprehensive Cancer Center and CEO of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He holds the John L. Marakas Nationwide Insurance Enterprise Foundation chair in cancer research and is a professor in The Ohio State University College of Medicine Departments of Molecular Virology, Immunology and Medical Genetics and Internal Medicine.

In Brief
  • Timothy Eberlein elected Chairman of NCCN Board of Directors

  • Carbone Cancer Center joins NCCN as member institution

  • Larry Kwak wins 2013 Ho-Am Prize in Medicine

  • Joel Helmke named senior vice president of operations at City of Hope
  • Anne Jadwin honored by Sigma Theta Tau nursing honor society

  • Paul Bushdid joins Southern Research

  • Dana Farber and Ontario Institute for Cancer Research join OHSU and Intel’s data cloud program

  • RareCyte signs CRADA with NCI

  • IBM launches Watson center in Milan, Italy

  • Schulman IRB selected for Cancer MoonShot 2020 program
Drugs and Targets
  • EU approves two-dose schedule for Gardasil 9

  • Halaven receives positive opinion from CHMP in liposarcomas

  • OncoBEAM RAS CRC test receives CE mark

  • University of Chicago and Evelo Biosciences enters licensing agreement

Copyright (c) 2020 The Cancer Letter Inc.